MediPharm Labs ( (TSE:LABS) ) has shared an announcement.
MediPharm Labs announced it will release its full year and fourth quarter financial results for 2024 on March 31, 2025. This announcement reflects the company’s ongoing commitment to transparency and its strategic positioning in the pharmaceutical cannabis industry. The release of these financial results is expected to provide insights into the company’s operational performance and its impact on stakeholders, as well as its continued expansion in international markets.
More about MediPharm Labs
MediPharm Labs, founded in 2015, is a pharmaceutical company specializing in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and advanced derivative products. The company operates a Good Manufacturing Practices certified facility and focuses on delivering precision-dosed cannabis products to domestic and international medical markets. MediPharm Labs holds a unique position in North America with a commercial-scale GMP license for cannabinoid extraction and has expanded its reach through strategic acquisitions, including VIVO Cannabis Inc.
YTD Price Performance: 82.50%
Average Trading Volume: 111,382
Technical Sentiment Signal: Sell
Current Market Cap: $29.08M
For a thorough assessment of LABS stock, go to TipRanks’ Stock Analysis page.